Head-To-Head Survey: iShares Biotechnology ETF (NASDAQ:IBB) vs. Nuveen New York Municipal Valu (NYSE:NNY)

Nuveen New York Municipal Valu (NYSE:NNY) and iShares Biotechnology ETF (NASDAQ:IBB) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Insider and Institutional Ownership

22.5% of Nuveen New York Municipal Valu shares are held by institutional investors. Comparatively, 62.5% of iShares Biotechnology ETF shares are held by institutional investors. 1.0% of Nuveen New York Municipal Valu shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Nuveen New York Municipal Valu has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, iShares Biotechnology ETF has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Dividends

Nuveen New York Municipal Valu pays an annual dividend of $0.06 per share and has a dividend yield of 0.7%. iShares Biotechnology ETF pays an annual dividend of $0.39 per share and has a dividend yield of 0.2%. Nuveen New York Municipal Valu has increased its dividend for 3 consecutive years. Nuveen New York Municipal Valu is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Nuveen New York Municipal Valu and iShares Biotechnology ETF, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuveen New York Municipal Valu	0	0	0	0	0.00
iShares Biotechnology ETF	0	6	2	0	2.71

iShares Biotechnology ETF has a consensus price target of $172.26, suggesting a potential upside of 0.00%. Given iShares Biotechnology ETF’s stronger consensus rating and higher possible upside, analysts plainly believe iShares Biotechnology ETF is more favorable than Nuveen New York Municipal Valu.

Earnings and Valuation

This table compares Nuveen New York Municipal Valu and iShares Biotechnology ETF”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuveen New York Municipal Valu	N/A	N/A	N/A	N/A	N/A
iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Nuveen New York Municipal Valu and iShares Biotechnology ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuveen New York Municipal Valu	N/A	N/A	N/A
iShares Biotechnology ETF	N/A	N/A	N/A

Summary

iShares Biotechnology ETF beats Nuveen New York Municipal Valu on 5 of the 8 factors compared between the two stocks.

About Nuveen New York Municipal Valu

Nuveen New York Municipal Value Fund, Inc. is a closed-ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of New York. The fund invests in tax exempt municipal bonds, with a rating of Baa/BBB or higher. It employs fundamental analysis, with bottom-up stock picking approach, to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor’s New York Municipal Bond Index and Standard & Poor’s National Municipal Bond Index. Nuveen New York Municipal Value Fund, Inc. was formed on October 7, 1987 and is domiciled in the United States.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.